Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy

HIV Medicine

Volumn 14, Issue 1, 2013, Pages 1-9

  Arildsen, H ^a   Sorensen K E ^a   Ingerslev, J M ^a   Ostergaard L J ^a   Laursen, A L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Coagulation; Endothelial function; HIV; Inflammation

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; VON WILLEBRAND FACTOR; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; FIBRINOLYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RISK ASSESSMENT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; VIRAL LOAD;

EID: 84870494221     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2012.01027.x     Document Type: Article

References (39)

1. Lohse N, Hansen AB, Pedersen G etal. Survival of persons with and without HIV infection in Denmark 1995-2005. Ann Intern Med 2007; 146: 87-95.
2. Obel N, Thomsen HF, Kromborg G etal. Ischemic heart disease in HIV-infected and HIV-uninfected individuals; a population-based cohort study. Clin Infect Dis 2007; 44: 1625-1631.
3. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-2512.
4. Friis-Moller N, Reiss P, Sabin CA etal. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
5. The strategies for management of antiretroviral therapy (SMART) group. CD4 count guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
6. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
7. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-2011.
8. Solages A, Vita JA, Thornton DJ etal. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42: 1325-1332.
9. Blanco JJR, García IS, Cerezo J etal. Endothelial function in HIV-infected patients with low or mild cardiovascular risk. J Antimicrob Chemother 2006; 58: 133-139.
10. Nolan D, Watts CF, Herrman SE, French MA, John M, Mallal S. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? QJM 2003; 96: 825-832.
11. De Gaetano Donati K, Rabagliati R, Tumbarello M etal. Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. AIDS 2003; 17: 765-768.
12. Sorensen KE, Celermajer DS, Spiegelhalter DJ etal. Non- invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995; 74: 247-253.
13. Celermajer DS, Sorensen KE, Georgakopoulos D etal. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88: 2140-2155.
14. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.
15. McLenachan JM, Williams JK, Fish RD, Ganz P, Selwin AP. Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation 1991; 84: 1273-1278.
16. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002; 40: 505-510.
17. Davies MJ, Gearing AJH, Pigott R, Woolf N, Katz D, Kyriakopoulos A. The expression of the adhesion molecules ICAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993; 171: 223-229.
18. Blankenberg S, Rupprecht HJ, Bickel C etal. Circulation cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104: 1336-1342.
19. Woolley IJ, Li X, Jacobsen LP, Palella FJ, Ostergaard L. Antibiotics and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. Sex Health 2007; 4: 111-119.
20. Dhawan SS, Quyyumi AD. Rheumatoid arthritis and cardiovascular disease. Curr Atheroscler Rep 2008; 10: 128-133.
21. Currier JS, Taylor A, Boyd F etal. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33: 506-512.
22. Mary-Krause M, Cotte L, Simon A, Partisan M. Costagliola D and the clinical epidemiology group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486.
23. Huang MB, Mahfuz K, Minerva GB, Powell M, Bond VC. Apoptotic effects in primary human umbilical veinendothelial cell cultures by exposure to virion-associated and cell membrane-associated HIV-1 gp120. J Acquir Immune Defic Syndr 2001; 27: 213-221.
24. Jia H, Lohr M, Jezequel S etal. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis. Biochem Biophys Res Commun 2001; 283: 469-479.
25. Dhawan S, Puri RK, Kumar A, Duplan H, Masson JM, Aggarwal BB. Human immunodeficiency virus-1 Tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule -1 in human endothelial cells. Blood 1997; 90: 1535-1544.
26. Kuller LH, Tracy R, Belloso W etal. INSIGHT SMART study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
27. Stein JH, Klein MA, Bellehumeur JL etal. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257-262.
28. Van Wijk JPH, de Koning EJP, Cabezas MC etal. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol 2006; 47: 1117-1123.
29. Lebech AM, Kristoffersen US, Wiinberg N etal. Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia. Eur J Nucl Med Mol Imaging 2008; 35: 2049-2058.
30. Torriani F, Komarow L, Parker RA etal. for the ATCG Study Group. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy. J Am Coll Cardiol 2008; 52: 569-575.
31. Oliviero U, Bonadies G, Apuzzi V etal. Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis 2009; 204: 586-589.
32. Melendez MM, McNurlan MA, Mynarcik DC, Khan S, Gelato MC. Endothelial adhesion molecules are associated with inflammation in subjects with HIV disease. Clin Infect Dis 2008; 46: 775-780.
33. Francisci D, Giannini S, Baldelli F etal. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 2009; 23: 589-596.
34. Kristoffersen US, Kofoed K, Kronborg G, Giger AK, Kjaer A, Lebech AM. Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med 2009; 10: 79-87.
35. Mastroianni CM, Lichtner M, Mengoni F etal. Changes in circulating levels of soluble cell adhesion molecules following highly active antiretroviral treatment of HIV-1 infected patients. Clin Immunol 2000; 95: 212-217.
36. Guimarãles MMM, Greco DB, de Figueiredo SM, Fóscolo RB, de Oliveira AR Jr, Machado LJC. High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection. Atherosclerosis 2008; 201: 434-439.
37. Madden E, Lee G, Kotler DP etal. Association of antiretroviral therapy with fibrinogen levels in HIVinfection. AIDS 2008; 22: 707-715.
38. Ford ES, Greenwald JH, Richterman AG etal. Traditional risk factors and D-dimers predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010; 24: 1509-1517.
39. Wolf K, Tsakiris DA, Weber R, Erb P. Battegay M, for the Swiss HIV Cohort Study. Antiviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type-1. J Infect Dis 2002; 185: 456-462.